You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

FLIBANSERIN - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for flibanserin and what is the scope of patent protection?

Flibanserin is the generic ingredient in one branded drug marketed by Sprout Pharms and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Flibanserin has forty-two patent family members in twenty-nine countries.

One supplier is listed for this compound.

Summary for FLIBANSERIN

International Patents:	42
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	19
Patent Applications:	556
Formulation / Manufacturing:	see details
What excipients (inactive ingredients) are in FLIBANSERIN?	FLIBANSERIN excipients list
DailyMed Link:	FLIBANSERIN at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FLIBANSERIN

Generic Entry Date for FLIBANSERIN^: ⤷ Try a Trial* Constraining patent/regulatory exclusivity: ⤷ Try a Trial Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FLIBANSERIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Andrew McDonald	Phase 2
Mohit Khera	Phase 2
Sprout Pharmaceuticals, Inc	Phase 2

See all FLIBANSERIN clinical trials

Pharmacology for FLIBANSERIN

Mechanism of Action	P-Glycoprotein Inhibitors

US Patents and Regulatory Information for FLIBANSERIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for FLIBANSERIN

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015	⤷ Try a Trial	⤷ Try a Trial
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015	⤷ Try a Trial	⤷ Try a Trial
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for FLIBANSERIN

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Slovenia	1446122		⤷ Try a Trial
European Patent Office	1446122	UTILISATION DE LA FLIBANSERINE DANS LE TRAITEMENT DE TROUBLES DU DESIR SEXUEL (USE OF FLIBANSERIN IN THE TREATMENT OF SEXUAL DESIRE DISORDERS)	⤷ Try a Trial
South Korea	20040047931		⤷ Try a Trial
South Korea	20090130196		⤷ Try a Trial
Montenegro	P42808		⤷ Try a Trial
New Zealand	532079	Use of flibanserin in the treatment of sexual disorders and desire	⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for FLIBANSERIN

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for FLIBANSERIN

Recent Clinical Trials for FLIBANSERIN

Pharmacology for FLIBANSERIN

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FLIBANSERIN